The Thesis
PanicFade v4 makes a specific, testable bet: negative headline shocks are overreacted to and tend to revert toward fundamentals. Operationally, it buys names where sentiment drops below -0.4 and price is already oversold (RSI14 below 35, trading under its SMA20), then sizes into the panic. It exits on reversion — RSI14 back above 50, or price reclaiming the SMA20 — and hard-stops on fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise. The design is grounded in recent sentiment-feedback literature (arXiv:2509.11970, 2025; corroborated by JRFM/MDPI's stock-level investor-sentiment work), which is a healthier provenance than most retrofitted contrarian rules.
The universe is deliberately conservative: 24 mega-cap and large-cap names across tech, financials, healthcare, staples, and energy. Fading panic works best where liquidity and fundamental floors are real, and this basket respects that.
Recent Activity
Here is the honest picture: nothing is happening right now. The six most recent scheduled runs (Aug 10 through Aug 17) each report 0 executed, 0 rejected, with the book sitting at $10,000 cash and $10,000 total. No qualifying panic has appeared — no name has cleared the sentiment-plus-oversold gate. That is the strategy working as designed, not a malfunction: a fade strategy with strict entry conditions should be dormant in calm, grinding-higher tape. But it also means the live track record is currently a flat line, and patience is the only position.
Backtest & Validation
The historical numbers are the strongest part of the case. Over 1,233 days the backtest returned 37.93% (6.79% CAGR), with a Sharpe of 0.96, a contained 9.3% max drawdown, and a 62.88% win rate across 530 trades.
More persuasive is the walk-forward validation, which passed cleanly. All 4 of 4 folds were positive, and — notably — improving: 1.6%, 3.88%, 10.14%, and 21.7%. The most recent out-of-sample fold posted a 2.44 Sharpe on just 2.6% drawdown. Aggregate OOS return was 21.7%, and the deflated statistics hold up: PSR of 0.985 and a DSR of 0.56 across 27 trials, meaning the edge survives an honest haircut for the number of variants tried.
Strengths and Risks
Strengths: literature-grounded thesis, monotonically improving folds, respectable drawdown control, and validation math that accounts for selection bias.
Risks worth flagging: the headline 37.93% is flattered by compounding — a 6.79% CAGR is modest. Turnover is enormous at 5,807%, so live slippage and fees (530 trade-fees in backtest) matter more than the clean equity curve suggests. A 0.96 in-sample Sharpe is decent, not exceptional, and the standout fold-4 Sharpe may not repeat. Finally, contrarian fades carry left-tail risk: the hard-stop-on-fresh-lows rule is the whole defense against buying a real collapse, and its live behaviour is still unproven. For now, PanicFade v4 is a well-validated strategy waiting for its moment.